Cargando…
Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Osimertinib (Tagrisso(®)) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mut...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300577/ https://www.ncbi.nlm.nih.gov/pubmed/30631243 http://dx.doi.org/10.1007/s40267-018-0536-9 |